PDL1+ Squamous cell carcinoma of the head and neck (SCCHN)

General concepts Brands Generic Side effects

Bispecific antibody Bavencio 5-fluorouracil (5-FU) Anemia
Combined positive score (CPS) Cytodrox Avelumab Constipation
Disease free survival (DFS) Droxiget Carboplatin Dermatitis
Epidermal growth factor receptor Durea Cetuximab Diarrhea
(EGFR) Erbitux Cisplatin Myelosuppression
Epithelial neoplasms Gindrea Docetaxel Nausea
Erythroplasia Imfinzi Durvalumab Neprhotoxicity
Human papillomavirus (HPV) Keytruda Hydroxyurea Neurotoxicity
Hypopharynx Lynparza Iniparib Ototoxicity
Immunohistochemistry (IHC) Opdivo Ipilimumab Renal failure
Larynx Paraplatin Lenvatinib Vomiting
Leukoplakia Platinol Methotrexate Xerostomia
Locally advanced SCCHN Rubraca Mitomycin Dysphagia
Lymph node metastasis Yervoy Nivolumab
Metastasized SCCHN Olaparib
Oral cavity Pembrolizumab
Oropharyngeal squamous cell Rucaparib
carcinoma (OPSCC) Tremelimumab
Oropharynx Veliparib
Overall response rate (ORR)
Overall survival (OS)
PD-L1 status
Platinum-refractory SCCHN
Predictive biomarker
Programmed cell death-1 (PD-1)
Programmed cell death-ligand 1 (PD-
L1)
Progression free survival (PFS)
Recurrent SCCHN
Tumor-infiltrating lymphocytes (TILs)
Upper aerodigestive tract
Vascular endothelial growth factor
(VEGF)

PDL1+ Squamous cell carcinoma of the head and neck (SCCHN)

Symptoms Treatments Others
Cough Anti CTLA-4 therapy
Chronic sinusitis Anti PD-1 Therapy
Dysphagia Chemotherapy
Dysphonia EXTREME regimen
Dyspnea Hyperfractionated accelerated
Epistaxis radiation therapy (HART)
Facial pain Immunotherapy
Halitosis Intratumor injections
Hoarseness Monoclonal antibody
Infections Platinum-based therapy
Lumps Radiochemotherapy
Lymphadenopathy Radiotherapy
Mucosal ulcerations Transoral robotic surgery (TORS)
Nerve palsies
Otalgia
Paresthesia
Sore throat
Stridor
Trismus
Weight loss